{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:48:51Z","timestamp":1781707731810,"version":"3.54.5"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":1028,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Orion Pharma"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Patients with advanced heart failure (AHF) who are not candidates to advanced therapies have poor prognosis. Some trials have shown that intermittent levosimendan can reduce HF hospitalizations in AHF in the short term. In this real-life registry, we describe the patterns of use, safety and factors related to the response to intermittent levosimendan infusions in AHF patients not candidates to advanced therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Multicentre retrospective study of patients diagnosed with advanced heart failure, not HT or LVAD candidates. Patients needed to be on the optimal medical therapy according to their treating physician. Patients with de novo heart failure or who underwent any procedure that could improve prognosis were not included in the registry. Four hundred three patients were included; 77.9% needed at least one admission the year before levosimendan was first administered because of heart failure. Death rate at 1 year was 26.8% and median survival was 24.7 [95% CI: 20.4\u201326.9] months, and 43.7% of patients fulfilled the criteria for being considered a responder lo levosimendan (no death, heart failure admission or unplanned HF visit at 1 year after first levosimendan administration). Compared with the year before there was a significant reduction in HF admissions (38.7% vs. 77.9%; P &amp;lt; 0.0001), unplanned HF visits (22.7% vs. 43.7%; P &amp;lt; 0.0001) or the combined event including deaths (56.3% vs. 81.4%; P &amp;lt; 0.0001) during the year after. We created a score that helps predicting the responder status at 1 year after levosimendan, resulting in a score summatory of five variables: TEER (+2), treatment with beta-blockers (+1.5), Haemoglobin &amp;gt;12 g\/dL (+1.5), amiodarone use (\u22121.5) HF visit 1 year before levosimendan (\u22121.5) and heart rate &amp;gt;70 b.p.m. (\u22122). Patients with a score less than \u22121 had a very low probability of response (21.5% free of death or HF event at 1 year) meanwhile those with a score over 1.5 had the better chance of response (68.4% free of death or HF event at 1 year). LEVO-D score performed well in the ROC analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this large real-life series of AHF patients treated with levosimendan as destination therapy, we show a significant decrease of heart failure events during the year after the first administration. The simple LEVO-D Score could be of help when deciding about futile therapy in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14278","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T07:00:53Z","timestamp":1674111653000},"page":"1193-1204","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Intermittent Inotropic Support with Levosimendan in Advanced Heart Failure as Destination Therapy: The LEVO-D Registry"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0716-254X","authenticated-orcid":false,"given":"David","family":"Dobarro","sequence":"first","affiliation":[{"name":"Hospital \u00c1lvaro Cunqueiro, Complexo Hospitalario Universitario de Vigo , Vigo ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Donoso-Trenado","sequence":"additional","affiliation":[{"name":"Hospital Universitari i Polit\u00e8cnic La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Sol\u00e9-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Hospital Clinic i Provincial , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Moliner-Ab\u00f3s","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau, IIB SANT PAU , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Garcia-Pinilla","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen de la Victoria, IBIMA, M\u00e1laga, Ciber-Cardiovascular, Instituto de Salud Carlos III, Departamento de Medicina y Dermatolog\u00eda, Universidad de M\u00e1laga , Malaga ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Lopez-Fernandez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen de las Nieves, ibs. GRANADA , Granada ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Ruiz-Bustillo","sequence":"additional","affiliation":[{"name":"Hospital del Mar , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Diez-Lopez","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n , Madrid ,","place":["Spain"]},{"name":"Hospital Universitari de Bellvitge - BIOHEART Research IDIBELL, Hospitalet del Llobregat , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Castrodeza","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"M\u00e9ndez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Hospital Universitari Vall d'Hebron , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vaqueriza-Cubillo","sequence":"additional","affiliation":[{"name":"Hospital Universitario Infanta Leonor , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cobo-Marcos","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro, IDIPHISA, Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Cardiovasculares (CIBERCV) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Tobar","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario de Valladolid , Valladolid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Sagasti-Aboitiz","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Cruces , Bizkaia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Universitario de Le\u00f3n , Le\u00f3n ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Escolar","sequence":"additional","affiliation":[{"name":"Hospital de Basurto , Bilbao ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Abecia","sequence":"additional","affiliation":[{"name":"Hospital de Navarra , Pamplona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Codina","sequence":"additional","affiliation":[{"name":"Hospital Germans Trias i Pujol , Badalona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"G\u00f3mez-Otero","sequence":"additional","affiliation":[{"name":"Complexo Hospitalario Universitario de Santiago , Santiago de Compostela ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Pastor","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen de la Arrixaca , Murcia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Marzoa-Rivas","sequence":"additional","affiliation":[{"name":"Hospital Arquitecto Marcide , Ferrol ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gonz\u00e1lez-Babarro","sequence":"additional","affiliation":[{"name":"Hospital de Montecelo, Complexo Hospitalario Universitario de Pontevedra , Pontevedra ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"de Juan-Baguda","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre, IMAS12, Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Cardiovasculares (CIBERCV), Departamento de Medicina, Facultad de ciencias biom\u00e9dicas y de la salud, Universidad Europea de Madrid , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Melendo-Viu","sequence":"additional","affiliation":[{"name":"Hospital \u00c1lvaro Cunqueiro, Complexo Hospitalario Universitario de Vigo , Vigo ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"de Frutos","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro, IDIPHISA, Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Cardiovasculares (CIBERCV) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Gonzalez-Costello","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n , Madrid ,","place":["Spain"]},{"name":"Hospital Universitari de Bellvitge - BIOHEART Research IDIBELL, Hospitalet del Llobregat , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"2026012114113110800_ehf214278-bib-0001","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2007.03.063","article-title":"IChronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID trial","volume":"50","author":"Rogers","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026012114113110800_ehf214278-bib-0002","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ahj.2007.10.020","article-title":"Characteristics of \u2018stage D\u2019 heart failure: insights from the acute decompensated heart failure National Registry Longitudinal Module (ADHERE LM)","volume":"155","author":"Costanzo","year":"2008","journal-title":"Am Heart J"},{"key":"2026012114113110800_ehf214278-bib-0003","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Outcomes of a prospective trial of intravenous Milrinone for exacerbations of chronic heart failure (OPTIME-CHF) investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"JAMA"},{"key":"2026012114113110800_ehf214278-bib-0004","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ejhf.1145","article-title":"LION-HEART study investigators. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial","volume":"20","author":"Com\u00edn-Colet","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012114113110800_ehf214278-bib-0005","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1002\/ehf2.13670","article-title":"Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study","volume":"8","author":"Garc\u00eda-Gonz\u00e1lez","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114113110800_ehf214278-bib-0006","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.recesp.2019.10.006","article-title":"Levosimendan as bridge to transplant in patients with advanced heart failure","volume":"73","author":"Ponz de Antonio","year":"2020","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026012114113110800_ehf214278-bib-0007","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijcard.2018.08.048","article-title":"RELEVANT-HF study group. Scheduled intermittent inotropes for ambulatory advanced heart failure. The RELEVANT-HF multicentre collaboration","volume":"272","author":"Oliva","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026012114113110800_ehf214278-bib-0008","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.118","article-title":"Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial","volume":"16","author":"Altenberger","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026012114113110800_ehf214278-bib-0009","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-terminal pro-B-type natriuretic peptide and clinical outcomes: Vericiguat heart failure with reduced ejection fraction study","volume":"8","author":"Ezekowitz","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026012114113110800_ehf214278-bib-0010","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.healun.2018.09.021","article-title":"Outcomes with ambulatory advanced heart failure from the medical arm of mechanically assisted circulatory support (MedaMACS) registry","volume":"38","author":"Ambardekar","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"2026012114113110800_ehf214278-bib-0011","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","article-title":"REVIVE heart failure study group. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure","volume":"1","author":"Packer","year":"2013","journal-title":"JACC Heart Fail"},{"key":"2026012114113110800_ehf214278-bib-0012","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","article-title":"A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure","volume":"344","author":"Beta-Blocker Evaluation of Survival Trial Investigators","year":"2001","journal-title":"N Engl J Med"},{"key":"2026012114113110800_ehf214278-bib-0013","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with Sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026012114113110800_ehf214278-bib-0014","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114113110800_ehf214278-bib-0015","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114113110800_ehf214278-bib-0016","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1161\/CIRCULATIONAHA.120.051122","article-title":"Two Tales: one story: EMPEROR-reduced and DAPA-HF","volume":"142","author":"Verma","year":"2020","journal-title":"Circulation"},{"key":"2026012114113110800_ehf214278-bib-0017","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004675","article-title":"Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction","volume":"6","author":"Gilstrap","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026012114113110800_ehf214278-bib-0018","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejhf.580","article-title":"Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial","volume":"18","author":"Vardeny","year":"2016","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14278","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/2\/1193\/65051147\/eschf_10_2_1193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/2\/1193\/65051147\/eschf_10_2_1193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:12:50Z","timestamp":1769022770000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/2\/1193\/8304893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1,19]]},"published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14278","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4]]},"published":{"date-parts":[[2023,1,19]]},"assertion":[{"value":"2022-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}